Valuation: TAUNS Laboratories,Inc.

Market Cap 56.61B 354M 320M 296M 268M 505M 33.29B 520M 3.52B 1.41B 17.83B 1.33B 1.3B P/E 2026 *
10.7x
P/E 2027 * 17.6x
Enterprise Value 64.6B 404M 366M 337M 305M 576M 37.99B 594M 4.02B 1.61B 20.35B 1.52B 1.48B EV / Sales 2026
-
EV / Sales 2027 * 4.18x
Free-Float
30.14%
Yield 2026 *
6.66%
Yield 2027 * 5.38%
Nov. 12 Kurabo Industries Ltd. entered into agreement to acquire 20.27% stake in TAUNS Laboratories,Inc. from CITIC Capital Japan Partners III, L.P. managed by Trustar Capital Inc., CCJP III Co-Investment, L.P. and Masaki Nonaka for ¥13.3 billion. CI
Aug. 26 TAUNS Laboratories,Inc. Announces Directorate Retirements, Effective September 25, 2026 CI
Aug. 19 Asia Pathogenomics Co., Ltd. announced that it has received funding from TAUNS Laboratories,Inc. CI
Aug. 18 Craif Inc. announced that it has received ¥3.4 billion in funding from a group of investors CI
Aug. 13 TAUNS Laboratories,Inc. Proposes Dividend for the Fiscal Year Ended June 30, 2026, Payable on September 28, 2026; Provides Dividend Guidance for the Second Quarter End and Full Fiscal Year Ending June 30, 2027 CI
Aug. 13 TAUNS Laboratories,Inc. Provides Earnings Guidance for the Fiscal Year Ending June 30, 2027 CI
Aug. 13 TAUNS Laboratories,Inc. Reports Earnings Results for the Full Year Ended June 30, 2026 CI
Jul. 14 Callisto Inc. announced that it expects to receive funding from TAUNS Laboratories,Inc. CI
Jul. 14 Provigate, Inc. announced that it expects to receive funding from TAUNS Laboratories,Inc. CI
May. 14 TAUNS Laboratories,Inc. Reports Earnings Results for the Nine Months Ended March 31, 2026 CI
May. 14 Tauns Laboratories,Inc. Provides Earnings Guidance for the Full Year Ending June 30, 2026 CI
Mar. 30 TAUNS Laboratories,Inc. Revises Earnings Guidance for the Year Ending June 30, 2026 CI
Feb. 13 TAUNS Laboratories,Inc. Reports Earnings Results for the Half Year Ended December 31, 2025 CI
1 day+9.50%
1 week+10.42%
Current month+7.94%
1 month+2.32%
3 months+11.58%
6 months+3.92%
Current year+4.13%
1 week 473
Extreme 473
554
1 month 473
Extreme 473
554
Current year 463
Extreme 463
568
1 year 463
Extreme 463
577
3 years 401
Extreme 401
733
5 years 401
Extreme 401
733
10 years 401
Extreme 401
733
Manager TitleAgeSince
Chief Executive Officer 51 2014-04-30
General Counsel 58 -
Comptroller/Controller/Auditor - -
Director TitleAgeSince
Director/Board Member 51 2014-04-30
Director/Board Member 53 2016-03-31
Director/Board Member 43 2020-08-31
Change 5-day change 1-year change 3-year change Capi.($)
+9.50%+10.42%-6.19% - 323M
-1.87%-7.15%-15.55%+14.13% 189B
-0.61%-3.78%+5.86%+42.88% 124B
-2.01%-8.03%-14.11%+14.17% 121B
-1.45%-4.87%-42.96%+2.86% 93.09B
-0.14%-1.31%-4.30%+76.84% 66.77B
+0.55%+3.12%+14.12%-8.07% 58.43B
-0.65%-0.08%-2.03%+62.81% 55.35B
+0.96%-1.33%-3.37%+57.35% 49.49B
+1.34%-4.74%-2.30%-7.18% 34.53B
Average +0.56%-2.01%-7.08%+28.42% 79B
Weighted average by Cap. -0.91%-3.10%-9.77%+26.14%

Financials

2026 2027 *
Net sales 14.76B 92.27M 83.49M 77.03M 69.77M 132M 8.68B 136M 918M 367M 4.65B 346M 339M 16.1B 101M 91.08M 84.03M 76.11M 143M 9.47B 148M 1B 400M 5.07B 378M 370M
Net income 5.2B 32.52M 29.43M 27.15M 24.59M 46.36M 3.06B 47.79M 324M 129M 1.64B 122M 120M 3.21B 20.08M 18.17M 16.76M 15.18M 28.62M 1.89B 29.51M 200M 79.87M 1.01B 75.4M 73.79M
Net Debt 7.99B 49.99M 45.23M 41.73M 37.8M 71.25M 4.7B 73.45M 497M 199M 2.52B 188M 184M 10.67B 66.72M 60.37M 55.7M 50.45M 95.1M 6.27B 98.03M 664M 265M 3.36B 251M 245M
Projected Income Statement - Annual - TAUNS Laboratories,Inc.
Logo TAUNS Laboratories,Inc.
Tauns Laboratories Inc is a Japan-based company engaged in the business of developing, manufacturing and marketing in vitro diagnostic products and research reagents. The Company operates its business in the in vitro diagnostic products business segment. The Company’s main product is antigen test kit that uses immunochromatography to enable rapid diagnosis at the patient's side without the need for special equipment. The products include ImunoAce Flu, ImunoAce SARSCoV-2 II, ImunoAce SARSCoV-2 Saliva, ImunoAce SARSCoV-2/Flu, ImunoAce Adeno, ImunoAce Strep A Neo, ImunoAce hMPV, ImunoAce Mycopiasma, ImunoAce RSV Neo and ImunoAce Noro.
Employees
218
Date Price Change Volume
26-11-12 ¥511.00 -3.58% 295,400
26-11-12 ¥530.00 +9.50% 3,203,900
26-11-11 ¥484.00 -0.62% 126,900
26-11-10 ¥487.00 +1.25% 122,600
26-11-09 ¥481.00 +1.05% 184,200
Trader
Investor
Global
Quality
ESG MSCI
-
MarketScreener Ratings - TAUNS Laboratories,Inc.
Sell
Consensus
Buy
Mean consensus
UNDERPERFORM
Number of Analysts
2
Last Close Price
530.00JPY
Average target price
420.00JPY
Spread / Average Target
-20.75%

Annual profits - Rate of surprise

Rate of surprise - EPS - Annual - TAUNS Laboratories,Inc.
  1. Stock Market
  2. Stocks
  3. 197A Stock